Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Cameron

Showing results (121-130 of 128) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 128 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 30, 2020
Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UKH M Earl, L Hiller, J Dunn, et al.
British Journal of Cancer|October 15, 2014
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancerJ Stephen, G Murray, D A Cameron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2017
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trialH R Ali, A Dariush, J Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis TrialH M Earl, L Hiller, J A Dunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerG N Hortobagyi, S M Stemmer, H A Burris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2018
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerG N Hortobagyi, S M Stemmer, H A Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.
Pageof 13

Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 30, 2020
Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UKH M Earl, L Hiller, J Dunn, et al.
British Journal of Cancer|October 15, 2014
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancerJ Stephen, G Murray, D A Cameron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2017
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trialH R Ali, A Dariush, J Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis TrialH M Earl, L Hiller, J A Dunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerG N Hortobagyi, S M Stemmer, H A Burris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2018
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerG N Hortobagyi, S M Stemmer, H A Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.
Pageof 13